Tobira Therapeutics Inc. (NASDAQ:TBRA) was down 4.2% on Monday . The company traded as low as $4.04 and last traded at $4.13, with a volume of 257,555 shares changing hands. The stock had previously closed at $4.31.

A number of equities research analysts have weighed in on TBRA shares. Cantor Fitzgerald downgraded shares of Tobira Therapeutics to a “buy” rating and set a $19.00 price target for the company. in a report on Monday, July 25th. Zacks Investment Research downgraded shares of Tobira Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. HC Wainwright reissued a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Cowen and Company reaffirmed a “buy” rating on shares of Tobira Therapeutics in a research note on Tuesday, May 10th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tobira Therapeutics in a research note on Tuesday, May 10th. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $16.95.

The firm’s 50-day moving average price is $10.51 and its 200 day moving average price is $8.60. The firm’s market cap is $76.11 million.

Tobira Therapeutics (NASDAQ:TBRA) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.12. Analysts forecast that Tobira Therapeutics Inc. will post ($2.49) earnings per share for the current fiscal year.

In other news, major shareholder A/S Novo sold 187,500 shares of the firm’s stock in a transaction on Monday, June 6th. The stock was sold at an average price of $10.37, for a total value of $1,944,375.00. Following the completion of the sale, the insider now directly owns 2,093,905 shares in the company, valued at $21,713,794.85. The sale was disclosed in a filing with the SEC, which is accessible through this link.

An institutional investor recently bought a new position in Tobira Therapeutics stock. Marshall Wace LLP acquired a new position in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned 0.57% of Tobira Therapeutics at the end of the most recent quarter.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.